List of Excipients in Branded Drug MITOMYCIN

Generic Drugs Containing MITOMYCIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	mitomycin	0143-9135	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	mitomycin	0143-9135	MANNITOL
Hikma Pharmaceuticals USA Inc	mitomycin	0143-9135	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	mitomycin	0143-9279	MANNITOL
Accord Healthcare Inc	mitomycin	16729-116	MANNITOL

What are the Most Frequently-Used Excipients in MITOMYCIN?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
22	MANNITOL
1	SODIUM HYDROXIDE

Mitomycin Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Mitomycin is a mature antineoplastic with three distinct formulation markets: conventional injectable powder, ophthalmic surgical delivery, and urologic intraluminal gel. The strongest commercial opportunity is not a new systemic excipient alone. It is a differentiated delivery system that improves mitomycin stability, local retention, preparation safety, dose consistency, or administration convenience while avoiding the patent and regulatory barriers around UroGen’s Jelmyto and its proprietary reverse-thermal gel platform.

What products currently use mitomycin, and how do their formulations differ?

Mitomycin is marketed primarily as a sterile lyophilized powder for injection, an ophthalmic surgical preparation, and a ready-to-use or reconstituted urologic gel system.

Product or category	Active ingredient	Route	Formulation model	Commercial owner or market position
Generic mitomycin for injection	Mitomycin	Intravenous or intravesical, depending on labeling	Sterile lyophilized powder requiring reconstitution	Multiple generic manufacturers
Mitosol	Mitomycin	Ophthalmic	Single-use kit with lyophilized mitomycin, diluent and filtration components	Mobius Therapeutics
Jelmyto	Mitomycin	Urologic, pyelocaliceal instillation	Mitomycin solution that forms a gel at body temperature	UroGen Pharma
Compounded ophthalmic mitomycin	Mitomycin	Topical ophthalmic or surgical	Pharmacy-compounded aqueous solution	Hospitals and compounding pharmacies

The formulation challenge varies by route. Injectable products must maintain chemical stability during storage and reconstitution. Ophthalmic products must control concentration, sterility, exposure time and surgeon workflow. Jelmyto must provide local drug retention in the upper urinary tract while allowing catheter administration and eventual urinary clearance.

The commercial value of an excipient strategy therefore depends on the route-specific problem being solved.

What excipient properties are most important for mitomycin?

Mitomycin has a narrow formulation margin. Useful excipient systems must address degradation, adsorption, pH control, osmolality, viscosity, sterility and operator handling without reducing antitumor activity.

Chemical stability

Mitomycin is generally more stable as a dry, lyophilized product than as an aqueous solution. Reconstituted solutions have limited stability and require controlled storage and use periods. The product label for mitomycin for injection instructs users to reconstitute the powder before administration and places restrictions on storage and handling of the resulting solution (DailyMed, 2024a).

Excipient strategies may include:

• Buffer systems that maintain a pH compatible with mitomycin stability.
• Bulking agents such as mannitol or other lyophilization-supporting materials.
• Cryoprotectants and lyoprotectants that preserve cake structure.
• Antioxidant systems, where chemically and toxicologically justified.
• Low-binding container and closure systems.
• Nitrogen headspace or oxygen-control packaging.
• Light-protective vials and secondary packaging.

The preferred strategy is usually to maximize dry-state stability rather than to create a highly stabilized aqueous product. A liquid formulation may create greater regulatory and commercial value, but it also increases degradation, extractables, sterility and shelf-life risks.

pH and osmolality control

For ophthalmic use, pH and osmolality directly affect tolerability. A buffer that improves mitomycin stability but increases ocular irritation may have limited clinical value. Intravesical and pyelocaliceal delivery provides more flexibility, but tissue exposure and urinary tract tolerability remain important.

Excipient selection should be supported by:

• Mitomycin degradation profiling across pH ranges.
• Compatibility testing with the intended catheter and administration set.
• Osmolality and viscosity measurements after reconstitution.
• Stability testing in the final container.
• Assessment of drug adsorption to plastic and elastomeric components.

Viscosity and local retention

The highest-value excipient opportunity is local-retention technology. Mitomycin has short residence time when delivered as a conventional aqueous solution. A mucoadhesive, thermoresponsive or in situ gelling system can increase local exposure and reduce premature washout.

Useful excipient classes include:

• Thermoresponsive polymers.
• Cellulose-derived polymers.
• Poloxamers.
• Mucoadhesive polymers.
• Polyethylene glycol-based systems.
• Biodegradable depot polymers.
• In situ cross-linking systems.

The formulation must balance retention against catheter deliverability. Excess viscosity can block catheters, increase administration time and create inconsistent dosing. A system that gels too rapidly may solidify before reaching the target site. A system that gels too slowly may be lost in urine before achieving therapeutic exposure.

What is the role of the Jelmyto excipient platform?

Jelmyto is the most commercially differentiated mitomycin formulation. The product is indicated for the treatment of low-grade upper tract urothelial cancer and uses a proprietary reverse-thermal gel technology designed to improve mitomycin retention in the pyelocaliceal system (FDA, 2021).

The product is supplied as a 40 mg single-dose vial and is prepared before administration. Its formulation and delivery system are central to its clinical and commercial differentiation. The platform is associated with UroGen’s RTGel technology and is not equivalent to a conventional mitomycin solution.

A competing excipient system would need to address at least one of four strategic objectives:

1. Provide comparable or superior upper-tract retention.
2. Reduce preparation complexity.
3. Improve catheter delivery and treatment tolerability.
4. Lower cost while preserving clinical performance.

A simple aqueous or mildly viscous formulation would face a weak value proposition against Jelmyto unless it had a substantial cost or convenience advantage. The more credible opportunity is a differentiated depot system with a clear pharmacokinetic or workflow benefit.

What formulation patents protect mitomycin delivery systems?

Mitomycin itself is an old small molecule and is not protected by meaningful composition-of-matter exclusivity in the United States. Commercial protection instead centers on:

• In situ gel compositions.
• Thermoresponsive polymer systems.
• Specific mitomycin concentrations and dosing regimens.
• Upper urinary tract delivery methods.
• Catheter-based administration.
• Treatment schedules for urothelial carcinoma.
• Container, kit and reconstitution systems.
• Manufacturing methods for the drug-delivery composition.

Jelmyto’s principal defensibility is based on formulation, delivery technology and clinical use rather than mitomycin molecule ownership. The FDA approved Jelmyto in April 2021 under the new drug application pathway for the treatment of low-grade upper tract urothelial cancer (FDA, 2021).

For a competing product, freedom-to-operate analysis should separate three layers:

IP layer	Main question	Commercial relevance
Polymer composition	Does the formulation use a protected thermoresponsive or mucoadhesive system?	Determines formulation design-around options
Method of use	Does the regimen overlap protected upper-tract cancer treatment claims?	May create Paragraph IV litigation exposure
Device and kit	Does the product rely on protected delivery or reconstitution components?	Affects catheter and packaging strategy

A new excipient platform may avoid direct overlap with a particular gel composition but still encounter method-of-use claims. The claims must be assessed at the full formulation, concentration, route, treatment schedule and device level.

What is the FDA regulatory status of mitomycin products?

Mitomycin for injection is an established generic product. Mitosol is an ophthalmic product approved for use in ophthalmic surgery. Jelmyto is an FDA-approved drug-device-like delivery product centered on local upper-tract administration.

Regulatory issue	Injectable mitomycin	Mitosol	Jelmyto
Regulatory pathway	Abbreviated or established-product pathway for generics	NDA-based ophthalmic product	NDA
Main CMC risk	Reconstitution stability and sterile powder quality	Kit consistency, filtration and ophthalmic sterility	Gel rheology, drug release and catheter administration
Main clinical risk	Systemic toxicity and route-specific exposure	Ocular toxicity	Ureteral obstruction, stenosis, infection and local urinary toxicity
Main commercial differentiator	Price and supply reliability	Surgical convenience and standardized preparation	Local retention and disease-specific efficacy
Excipient sensitivity	Moderate	High	Very high

A new mitomycin formulation is unlikely to qualify as a simple generic if it changes the dosage form, excipient system, local exposure profile or route-specific delivery behavior. A 505(b)(2) strategy may be more appropriate for a reformulated local-delivery product, depending on the proposed indication and the degree of reliance on existing mitomycin data.

When does mitomycin lose exclusivity, and what does that mean for excipient opportunities?

Mitomycin is an off-patent active ingredient with generic competition. The commercial opportunity is therefore concentrated in differentiated formulations, hospital supply contracts, specialty administration and route-specific products.

Jelmyto has regulatory exclusivity and patent-related protection distinct from older mitomycin products. FDA approved the product in 2021, and its commercial protection depends on the combination of statutory exclusivity, listed patents and any later patent or regulatory developments (FDA, 2021; FDA, 2024).

For investors and developers, the relevant timeline is not the expiration of mitomycin molecule patents. It is the timing of:

• Jelmyto’s listed patent expiry dates.
• Paragraph IV challenges.
• Potential settlements.
• 505(b)(2) entry.
• Clinical adoption of alternative local-delivery systems.
• Hospital and urology practice conversion costs.

A reformulated product may enter before a direct generic gel if it has a distinct formulation, indication or delivery profile. The product must still avoid infringement and establish adequate safety and efficacy for the proposed use.

How strong is the patent estate for a mitomycin excipient product?

Patent strength depends on claim breadth, enablement, formulation complexity and the ability to design around the polymer system.

Stronger claim categories

Claims are generally more commercially useful when they cover:

• A defined polymer composition with narrow but reproducible rheology.
• A formulation that transitions from liquid to gel at a clinically relevant temperature.
• Specific mitomycin loading and release characteristics.
• Upper-tract delivery with a defined treatment schedule.
• A kit integrating the drug, gel system and administration components.
• A manufacturing process that produces a stable and consistent formulation.

Weaker claim categories

Claims are more vulnerable when they cover:

• Broad lists of conventional excipients.
• Generic statements that a polymer can improve retention.
• Unrestricted combinations of mitomycin with common viscosity agents.
• Formulations without demonstrated release or pharmacokinetic advantages.
• Methods that replicate an established treatment regimen without a distinct technical feature.

A robust patent program should include composition, use, manufacturing and device claims. One patent family rarely provides sufficient protection for a high-value specialty formulation.

Which excipient strategies offer the strongest commercial opportunity?

Ready-to-use injectable mitomycin

A liquid, ready-to-use injectable could reduce pharmacy compounding and hazardous-drug preparation. The principal technical obstacles are aqueous stability, container compatibility and shelf life.

Commercial value would be highest in:

• Oncology centers with high preparation volumes.
• Hospitals seeking reduced compounding labor.
• Products that reduce vial waste.
• Closed-system transfer systems.
• Standardized low-dose administration.

The product would compete mainly on workflow and total cost of ownership, not on new clinical efficacy.

Improved ophthalmic mitomycin system

Ophthalmic mitomycin is used in procedures such as glaucoma surgery and refractive or corneal interventions. A premeasured, preservative-free, ready-to-use system could reduce dilution errors and variability in surgical exposure.

Potential formats include:

• Single-use prefilled syringes.
• Unit-dose preservative-free solutions.
• Stabilized low-volume vials.
• Drug-soaked delivery sponges with controlled loading.
• Kits with validated exposure-time controls.

The regulatory burden is substantial because ocular toxicity is concentration- and exposure-dependent. The commercial advantage must be demonstrated through preparation accuracy, sterility, surgeon workflow and consistent tissue exposure.

Alternative upper-tract depot system

This is the largest formulation opportunity. A competing product could use a different thermoresponsive or mucoadhesive platform to offer:

• Longer residence time.
• Lower mitomycin dose.
• Fewer instillations.
• Reduced urinary tract obstruction.
• Better catheter flow.
• More predictable gel dissolution.
• Lower manufacturing cost.

A product with materially improved tolerability could compete even without matching Jelmyto’s exact clinical profile. The key endpoint would be whether the formulation improves the treatment experience without compromising local antitumor exposure.

Intravesical retention system

A bladder-directed mitomycin formulation could target non-muscle-invasive bladder cancer or post-resection therapy. The market is more competitive and includes established intravesical chemotherapy, device-assisted delivery and immunotherapy options.

The strongest opportunity would be a formulation that:

• Maintains bladder exposure for longer than an aqueous instillation.
• Reduces treatment time.
• Limits systemic absorption.
• Is compatible with standard catheter workflows.
• Has a differentiated indication or treatment schedule.

What manufacturing and IP barriers affect commercial development?

Mitomycin is a hazardous cytotoxic compound. Manufacturing requires containment, validated cleaning, operator protection and specialized waste handling. A formulation may be technically simple but commercially unattractive if it increases occupational exposure or creates difficult aseptic-processing steps.

Major manufacturing barriers include:

• Uniform drug distribution in polymer systems.
• Control of gel viscosity across batches.
• Sterile filtration limitations for viscous formulations.
• Terminal sterilization incompatibility.
• Mitomycin degradation during mixing or filling.
• Extractables and leachables from delivery components.
• Drug adsorption to tubing and catheters.
• Long-term stability in single-use devices.
• Reproducible reconstitution at the point of care.

A liquid formulation may require aseptic processing and cold-chain controls. A lyophilized product may simplify stability but preserve the preparation burden. A dual-chamber or cartridge system could resolve this tradeoff but would increase device-development and combination-product complexity.

What generic entry risks exist for Jelmyto and other mitomycin products?

Generic entry risk is highest for conventional mitomycin injection because the product is mature and multiple suppliers compete on price. The risk is lower for complex local-delivery products because equivalence requires more than matching the active ingredient.

For Jelmyto-like products, a challenger may need to establish:

• Pharmaceutical equivalence or a justified 505(b)(2) relationship.
• Comparable local exposure.
• Comparable gel formation and residence time.
• Consistent catheter administration.
• Acceptable local safety.
• Freedom to operate around formulation and use patents.

A Paragraph IV challenge could trigger litigation under the Hatch-Waxman framework if the reference product has listed patents in the Orange Book. The commercial timing would depend on patent certification, litigation, possible 30-month stay, settlement terms and the challenger’s regulatory approval. A later entrant could also pursue a non-infringing 505(b)(2) product with a distinct excipient or delivery platform.

How does mitomycin compare with competing local-delivery drugs?

Attribute	Conventional mitomycin	Jelmyto	Gemcitabine intravesical products	Device-assisted chemotherapy
Main value proposition	Low cost and established use	Upper-tract local retention	Established bladder chemotherapy	Enhanced local exposure
Excipient opportunity	Stability and ready-to-use presentation	Design-around gel or improved depot	Retention and reduced instillation burden	Device-drug integration
Main barrier	Commodity pricing	Patents, clinical data and safety	Competitive treatment protocols	Capital equipment and workflow
Generic risk	High	Moderate to low near term	Moderate	Lower if device-dependent
Commercial differentiation	Convenience and supply	Clinical outcome and residence time	Treatment duration and tolerability	Pharmacokinetics and procedure integration

Mitomycin’s main competitive weakness is its toxicity and formulation sensitivity. Its main strength is the extensive clinical experience and low active-ingredient cost. A successful excipient product must convert those strengths into a safer, more standardized local-delivery experience.

What licensing and partnership opportunities exist?

Licensing opportunities are most attractive in four areas:

1. Thermoresponsive or mucoadhesive polymer platforms with prior clinical use.
2. Ready-to-use hazardous-drug delivery systems.
3. Ophthalmic unit-dose packaging and controlled-exposure devices.
4. Catheter-compatible drug-depot systems.

Potential partners include:

• Specialty oncology companies.
• Urology-focused pharmaceutical companies.
• Ophthalmic drug manufacturers.
• Contract development and manufacturing organizations.
• Polymer technology companies.
• Catheter and combination-product manufacturers.

A platform license should cover commercial use, field exclusivity, polymer supply, analytical methods, regulatory support and rights to improvements. The critical diligence issue is whether the platform can be used with mitomycin without triggering third-party composition, method-of-use or device patents.

What is the revenue exposure and commercial upside?

The generic injectable market has limited margin potential because active-ingredient cost is low and purchasing is price-sensitive. The commercial upside is higher in specialty formulations that command reimbursement based on clinical benefit or reduced treatment burden.

Opportunity	Margin potential	Development risk	Differentiation potential
Generic injectable powder	Low	Low to moderate	Low
Ready-to-use injectable	Moderate	Moderate	Moderate
Ophthalmic unit-dose kit	Moderate to high	Moderate	Moderate
Intravesical retention formulation	High	High	High
Upper-tract gel alternative	High	High	Very high
Drug-device combination	High	Very high	High

Revenue exposure is concentrated in the ability to secure a differentiated indication and maintain reimbursement. A technically superior excipient does not create value if physicians must change established catheter, pharmacy or operating-room workflows without a clear clinical benefit.

Key Takeaways

• Mitomycin is an off-patent active ingredient; the strongest IP opportunities are formulation, delivery, method-of-use and device claims.
• The commercial market divides into injectable, ophthalmic and urologic products.
• The most valuable excipient opportunity is a local-retention system for upper-tract or bladder delivery.
• Jelmyto establishes the commercial value of thermoresponsive mitomycin delivery but also creates significant patent, clinical and regulatory barriers.
• Ready-to-use injectable and ophthalmic products can create value through reduced preparation errors, lower waste and better workflow.
• Conventional generic mitomycin has high generic-entry risk and limited margin potential.
• Any competing gel or depot product requires a detailed freedom-to-operate review covering polymer composition, treatment regimen, catheter delivery and manufacturing claims.
• Manufacturing control of viscosity, sterility, drug stability and catheter compatibility will determine whether a formulation can scale commercially.
• Biosimilar risk is not relevant because mitomycin is a small-molecule cytotoxic drug, not a biologic.
• The strongest licensing targets are clinically validated polymer platforms and combination-product technologies with established aseptic manufacturing capability.

FAQs About Mitomycin Excipient Commercialization

Can mannitol be used in a commercial mitomycin formulation?

Mannitol is commonly used as a lyophilization bulking agent and may support cake formation in sterile powder products. Its suitability depends on mitomycin stability, reconstitution performance, osmolality and compatibility with the intended route.

What is the best polymer for a mitomycin upper-tract gel?

There is no universally optimal polymer. The development target is a system that remains deliverable through a catheter, gels at physiological temperature, retains mitomycin locally and clears without causing obstruction or unacceptable urinary toxicity.

Could a ready-to-use mitomycin injection replace lyophilized products?

It could reduce reconstitution work and preparation variability, but it would need sufficient aqueous shelf life, container compatibility, sterility assurance and acceptable hazardous-drug handling characteristics.

Is a mitomycin formulation eligible for a 505(b)(2) application?

A reformulated product may be suitable for a 505(b)(2) pathway when it relies partly on existing mitomycin data but introduces a new dosage form, route, delivery system or indication. The final pathway depends on the extent of clinical bridging and the proposed labeling.

What is the largest unmet need in mitomycin delivery?

The largest unmet need is a local-delivery system that improves upper-tract or bladder retention while reducing administration complexity, urinary tract toxicity and treatment burden.

References

1. DailyMed. (2024a). Mitomycin for injection, USP: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2021). FDA approves mitomycin for pyelocaliceal solution for low-grade upper tract urothelial cancer. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Jelmyto: Prescribing information. U.S. National Library of Medicine, DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2012). Mitosol kit: Approval letter and prescribing information. https://www.fda.gov/